ethyl 3-[3-(2-aminoethyl)-5-(3-pyridylmethyl)phenyl]propanoate | 145691-97-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-[3-(2-aminoethyl)-5-(3-pyridylmethyl)phenyl]propanoate
• 英文别名: ethyl 3-[3-(2-aminoethyl)-5-(pyridin-3-ylmethyl)phenyl]propanoate
• CAS: 145691-97-0
• 化学式: C₁₉H₂₄N₂O₂
• 分子量: 312.412
• InChiKey: XBNUDWVMQPMVCR-UHFFFAOYSA-N

物化性质

• 沸点：
  460.2±40.0 °C(Predicted)
• 密度：
  1.098±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-[3-(2-aminoethyl)-5-(3-pyridylmethyl)phenyl]propanoate 在 sodium hydride 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 7.5h， 生成 3-(3-{2-[(4-Chloro-benzenesulfonyl)-methyl-amino]-ethyl}-5-pyridin-3-ylmethyl-phenyl)-propionic acid ethyl ester
  参考文献：
  名称：

  Dickinson, Roger P.; Dack, Kevin N.; Long, Clive J., Journal of Medicinal Chemistry, 1997, vol. 40, # 21, p. 3442 - 3452

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氰基吡啶 在 palladium on activated charcoal palladium diacetate 、 氢氧化钾 、 sodium hydroxide 、 正丁基锂 、 叠氮磷酸二苯酯 、 甲酸铵 、 一水合肼 、 乙二醇 、 三乙胺 、 三(邻甲基苯基)磷 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 28.5h， 生成 ethyl 3-[3-(2-aminoethyl)-5-(3-pyridylmethyl)phenyl]propanoate
  参考文献：
  名称：

  Dickinson, Roger P.; Dack, Kevin N.; Long, Clive J., Journal of Medicinal Chemistry, 1997, vol. 40, # 21, p. 3442 - 3452

  摘要：

  DOI：

文献信息

• Pyridine derived agents for cardiovascular diseases
  申请人：Pfizer Inc.

  公开号：US05457118A1

  公开（公告）日：1995-10-10

  ##STR1## Compounds of formula (I) or a biolabile ester thereof, or a pharmaceutically acceptable salt of either, wherein R.sup.l, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from H or C.sub.1 -C.sub.4 alkyl; R.sup.5 is (CH.sub.2).sub.m SO.sub.2 R.sup.6, (CH.sub.2).sub.m NHSO.sub.2 R.sup.6 or (CH.sub.2).sub.m NHCOR.sup.7 ; R.sup.6 and R.sup.7 are C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.3 perfluoroalkyl(CH.sub.2).sub.n, C.sub.3 -C.sub.6 cycloalkyl(CH.sub.2).sub.n, aryl(CH.sub.2).sub.n or heteroaryl(CH.sub.2).sub.n ; or R.sup.6 is NR.sup.8 R.sup.9 ; R.sup.8 is H or C.sub.1 -C.sup.4 alkyl; R.sup.9 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl(CH.sub.2).sub.n, aryl(CH.sub.2).sub.n or heteroaryl(CH.sub.2).sub.n ; or R.sup.8 and R.sup.9 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may optionally incorporate a carbon-carbon double bond or a further hetero atom linkage selected from O, S, NH, N(C.sub.1 -C.sub.4 alkyl) and N(C.sub.1 -C.sub.5 alkanoyl), and which may optionally be substituted with one to three substituents each independently selected from C.sub.1 -C.sub.4 alkyl and C.sub.1 -C.sub.4 alkoxy, and which may optionally be benzo-fused; X is CH.sub.2, CHCH.sub.3, C(OH)CH.sub.3, C.dbd.CH.sub.2 or O; m is 0 or 1; n is 0, 1, 2 or 3; and Het is 3- or 4-pyridyl or 1-imidazolyl; with the proviso that when Het is 1-imidazolyl then X is CH.sub.2 or CHCH.sub.3, are combined thromboxane A.sub.2 synthetase inhibitors and thromboxane A.sub.2 /endoperoxide antagonists of utility in the treatment of disease conditions in which thromboxane A.sub.2 is a causative agent.

  式(I)的化合物或其生物易降解酯，或者它们的药用可接受的盐，其中R.sup.l、R.sup.2、R.sup.3和R.sup.4分别独立地选择自H或C.sub.1-C.sub.4烷基；R.sup.5为(CH.sub.2).sub.m SO.sub.2 R.sup.6、(CH.sub.2).sub.m NHSO.sub.2 R.sup.6或(CH.sub.2).sub.m NHCOR.sup.7；R.sup.6和R.sup.7为C.sub.1-C.sub.6烷基，C.sub.1-C.sub.3全氟烷基(CH.sub.2).sub.n，C.sub.3-C.sub.6环烷基(CH.sub.2).sub.n，芳基(CH.sub.2).sub.n或杂芳基(CH.sub.2).sub.n；或R.sup.6为NR.sup.8 R.sup.9；R.sup.8为H或C.sub.1-C.sup.4烷基；R.sup.9为C.sub.1-C.sub.6烷基，C.sub.3-C.sub.6环烷基(CH.sub.2).sub.n，芳基(CH.sub.2).sub.n或杂芳基(CH.sub.2).sub.n；或R.sup.8和R.sup.9与它们连接的氮原子一起形成一个5-至7-成员杂环，该杂环可以选择性地包含一个碳-碳双键或进一步的来自O、S、NH、N(C.sub.1-C.sub.4烷基)和N(C.sub.1-C.sub.5醇酰)的杂原子键合，并且可以选择性地用每个独立选择自C.sub.1-C.sub.4烷基和C.sub.1-C.sub.4烷氧基的一个到三个取代基取代，也可以选择性地与苯融合；X为CH.sub.2、CHCH.sub.3、C(OH)CH.sub.3、C.dbd.CH.sub.2或O；m为0或1；n为0,1,2或3；Het为3-或4-吡啶基或1-咪唑基；但是当Het为1-咪唑基时，X为CH.sub.2或CHCH.sub.3，结合了血栓素A.sub.2合成酶抑制剂和血栓素A.sub.2/内过氧化物拮抗剂，用于治疗血栓素A.sub.2是致病因素的疾病条件。
• Pyridine- and imidazole-derived agents for cardiovascular diseases
  申请人：Pfizer Inc.

  公开号：US05705523A1

  公开（公告）日：1998-01-06

  Compounds of formula: ##STR1## or a biolabile ester thereof, or a pharmaceutically acceptable salt of either, wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from H or C.sub.1 -C.sub.4 alkyl; R.sup.5 is (CH.sub.2).sub.m SO.sub.2 R.sup.6, (CH.sub.2).sub.m NHSO.sub.2 R.sup.6 or (CH.sub.2).sub.m NHCOR.sup.7 ; R.sup.6 and R.sup.7 are C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.3 perfluoroalkyl-(CH.sub.2).sub.n, C.sub.3 -C.sub.6 cycloalkyl(CH.sub.2).sub.n, aryl(CH.sub.2).sub.n or heteroaryl(CH.sub.2).sub.n ; or R.sup.6 is NR.sup.8 R.sup.9 ; R.sup.8 is H or C.sub.1 -C.sub.4 alkyl; R.sup.9 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl(CH.sub.2).sub.n, aryl(CH.sub.2).sub.n or heteroaryl(CH.sub.2).sub.n ; or R.sup.8 and R.sup.9 together with the nitrogen atom to which they are attached from a 5- to 7-membered heterocyclic ring; X is CH.sub.2, CHCH.sub.3, C(OH)CH.sub.3, C.dbd.CH.sub.2 or O; m is 0 or 1; n is 0, 1, 2 or 3; and Het is 3- or 4-pyridyl or 1-imidazolyl; are combined thromboxane A.sub.2 synthetase inhibitors and thromboxane A.sub.2 /endoperoxide antagonists of utility in the treatment of disease conditions in which thromboxane A.sub.2 is a causative agent.

  化合物的公式为：##STR1## 或其生物可降解酯，或其药学上可接受的盐，其中R.sup.1，R.sup.2，R.sup.3和R.sup.4各自独立地选择H或C.sub.1-C.sub.4烷基；R.sup.5为(CH.sub.2).sub.m SO.sub.2R.sup.6，(CH.sub.2).sub.m NHSO.sub.2R.sup.6或(CH.sub.2).sub.m NHCOR.sup.7；R.sup.6和R.sup.7为C.sub.1-C.sub.6烷基，C.sub.1-C.sub.3全氟烷基-(CH.sub.2).sub.n，C.sub.3-C.sub.6环烷基(CH.sub.2).sub.n，芳基(CH.sub.2).sub.n或杂芳基(CH.sub.2).sub.n；或R.sup.6为NR.sup.8R.sup.9；R.sup.8为H或C.sub.1-C.sub.4烷基；R.sup.9为C.sub.1-C.sub.6烷基，C.sub.3-C.sub.6环烷基(CH.sub.2).sub.n，芳基(CH.sub.2).sub.n或杂芳基(CH.sub.2).sub.n；或R.sup.8和R.sup.9与它们所连接的氮原子形成5-至7-成员杂环；X为CH.sub.2，CHCH.sub.3，C(OH)CH.sub.3，C.dbd.CH.sub.2或O；m为0或1；n为0，1，2或3；和Het为3-或4-吡啶基或1-咪唑基。这些化合物是血栓素A.sub.2合成酶抑制剂和血栓素A.sub.2/内过氧化物拮抗剂，适用于治疗血栓素A.sub.2是致病因素的疾病条件。
• PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES
  申请人：Pfizer Limited

  公开号：EP0579618A1

  公开（公告）日：1994-01-26
• US5457118A
  申请人：——

  公开号：US5457118A

  公开（公告）日：1995-10-10
• US5705523A
  申请人：——

  公开号：US5705523A

  公开（公告）日：1998-01-06